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ABSTRACT 
 
Dietary Apigenin and Naringenin Protect Against Colon Carcinogenesis by  
Lowering High Multiplicity Aberrant Crypt Foci and Enhancing Apoptosis in  
Azoxymethane-Treated Rats. (May 2005) 
Tety Leonardi, B.S., Texas A&M University 
Co-Chairs of Advisory Committee:  Dr. Nancy D. Turner 
 Dr. Joanne R. Lupton 
 
 
 
Colon cancer is the third most common cancer in the United States. However, 
evidence indicates that a proper diet abundant in fruits and vegetables may be protective 
against colon cancer development. Bioactive compounds in fruits and vegetables, such 
as flavonoids and limonoids, have been shown to possess anti-proliferative and anti-
tumorigenic effects in various in vitro and in vivo models of cancer. Since there are few 
animal studies involving flavonoids and limonoids and colon cancer, this experiment 
investigated the potentially protective effects of four citrus flavonoids and one limonoid 
mixture against the promotion stage of chemically-induced colon cancer in rats. Male 
SD rats (n =60; 10 rats/group) were assigned to receive diets containing 0.1% apigenin, 
0.02% naringenin, 0.1% hesperidin, 0.01% nobiletin, 0.035% limonin 
glucoside/obacunone glucoside mixture, or a control diet (0% flavonoid/limonoid). Rats 
received the diets for 10 wk and were injected with azoxymethane (15 mg/kg) at wk 3 
and 4. The excised colons were evaluated for aberrant crypt foci (ACF) formation, cell 
proliferation (PCNA assay), apoptosis (TUNEL assay), and iNOS and COX-2 
expression. When compared to the control diet, apigenin lowered the number of high 
multiplicity ACF (> 4 AC/focus) by 57% (P<0.05) and tended to lower the proliferative 
index (28%; P=0.07), while naringenin lowered both the number of high multiplicity 
ACF by 51% (P<0.05) and the proliferative index by 32% (P<0.05). Both apigenin and 
naringenin increased apoptosis of surface colon cells (78% and 97%, respectively; 
P<0.05) when compared to control diet. Hesperidin, nobiletin, and the limonin 
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glucoside/obacunone glucoside mixture did not have any effects on the above variables 
measured in this model of colon carcinogenesis. The colonic mucosal protein levels of 
iNOS or COX-2 were not different among the six diet groups. Evidence suggests that 
high multiplicity ACF are indicative of future tumor development in both humans and 
rats. Furthermore, dysregulated proliferation and apoptosis may also lead to 
tumorigenesis. Therefore, the ability of dietary apigenin and naringenin to reduce high 
multiplicity ACF, lower proliferation, and increase apoptosis may contribute toward 
colon cancer prevention.  However, their protection is not due to their influence on iNOS 
and COX-2 protein levels.  
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CHAPTER I 
 
INTRODUCTION 
 
It was estimated that by the end of the year 2004, approximately 1,500 
Americans a day would have died of cancer, accounting for about one in four deaths (1). 
Out of the total number of deaths from cancer, the American Cancer Society projected 
that more than 100,000 new cases of colon cancer would be diagnosed and more than 
56,000 deaths from colorectal cancer would occur in the United States (1). These 
statistics make colon cancer the third most common cancer in men and women 
individually, and the second leading cause in cancer mortality when numbers for men 
and women are combined (1). The 5-y survival rate following diagnosis of colon cancer 
is about 63% in the United States (2). In addition, the total economic burden of cancer 
imposed on society was estimated to be $143.5 billion in 1996, the most recent year for 
which data were available (3). This figure included both the direct costs of cancer care 
and treatments and the indirect costs of productivity loss due to cancer illness and 
deaths. The costs associated with colorectal cancer alone accounted for about 13.1% of 
the total economic burden for all cancers (3). 
Despite the unfavorable incidence of colon cancer, the 1999 Harvard Report on 
Cancer Prevention stated that colon cancer may be preventable when risk factors such as 
diet and lifestyle are modified (4). Furthermore, the implication of diet and lifestyle as 
probable risk factors for colon cancer was evidenced by studies of individuals migrating 
from low- to high-risk areas (5,6). Diet and its relationship with cancer have interested 
many scientists and is a topic of ongoing research. Where colon cancer is concerned, 
many scientists, backed by a large body of evidence, believe that a proper diet, 
especially one high in fruits and vegetables, may be protective against colon cancer 
development [reviewed in (7-9)]. This is an area of great contention, however, as others 
have found little or no relationship between consumption of fruits and vegetables and 
colon cancer (10-14).  
_______________ 
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  Nonetheless, more research in this area is warranted as new data emerge with 
promising associations between components in fruits and vegetables and the prevention 
of colon carcinogenesis. In a recent prospective cohort study of Swedish women, the risk 
of colon cancer was greatest for those with the lowest intake of fruits and vegetables, 
with fruit consumption having the greater association with lowered risk (6). A 
population study by Risch et al. (15) suggested that fruits, especially citrus fruits, contain 
biologically active compounds besides vitamin C that may play a role in preventing 
many chronic diseases including cancer. Although, to the best of our knowledge, there is 
no human studies specifically linking citrus fruits to lowered colon cancer risk, the use 
of citrus peel by subjects in Arizona was associated with a reduced risk of squamous cell 
carcinoma of the skin (16). However, some animal studies have reported some 
protection against developing colonic tumors from consuming citrus fruits. For example, 
feeding either orange juice (17) or 15% orange-pulp diet (18) was able to suppress 
chemically induced colon tumors in rats. Bioactive compounds such as certain 
flavonoids and limonoids have been suggested to be among the promising 
chemopreventive agents in citrus fruits (19). Recent experimental data also provide 
evidence that certain citrus flavonoids and limonoids may be protective against several 
cancers, including colon cancer (20-34). 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Multistage colon carcinogenesis.  The development of carcinogenesis is a 
multistep process involving the genetic mutation of normal cells (the initiation stage), 
transformation into and subsequent accretion of cells with abnormal phenotype through 
epigenetic mechanisms and alterations in cell dynamics (the promotion stage), and 
finally progressing into dysplastic, invasive, and metastatic cancer (the progression 
stage) (35). Very often, the process of carcinogenesis is the result of accumulated 
progressive changes in the expression of proto-oncogenes, tumor suppressor genes, 
apoptosis-regulating genes, and DNA repair genes  all causing the affected cells to 
acquire genetic instability (35).  
Several major pathways to colon cancer development have been proposed 
[reviewed in (5,36,37)]. One major pathway involves an inherited or acquired mutation 
in the adenomatus polyposis coli (APC) gene, a tumor suppressor gene, which controls 
cell replication, adhesion, and migration via the wingless type (Wnt)/β-catenin pathway. 
Activation of the Wnt/APC/β-catenin pathway is said to enhance the expression of genes 
controlling cell growth and tumorigenesis. Also associated with this pathway are 
alterations in DNA methylation patterns and genetic changes such as the mutation of K-
ras (a proto-oncogene) and mutation or loss of p53 (a tumor-supressor gene). Another 
pathway involves microsatelite instability (36,37) of the affected cells caused by 
mutation, loss, or epigenetic hypermethylation in DNA mismatch repair (MMR) genes. 
Implicated in this pathway are transforming growth factor (TGF) β receptor II gene, 
which controls growth, and BAX gene, which controls apoptosis. One other pathway is 
via the inflammatory bowel disease (IBD) dysplasia-carcinoma sequence involving 
chronic inflammation and loss of epithelial integrity (5). Patients with ulcerative colitis 
and Crohns disease, both categorized under IBD, have about a 20-fold excess risk of 
colon cancer than when IBD is not present (5). As will be discussed later, chronic 
inflammation creates a favorable environment for the promotion of cancer. 
Hypermethylation silencing of the estrogen receptor gene is also suggested as a separate 
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pathway to colon cancer (5,38). After the initial genetic modifications, however, the 
promotion of abnormal cells into subsequent colon adenocarcinoma takes many years to 
develop (36,37,39). This long latent period allows certain factors, including diet, a 
chance to modulate the disease (4,39).  
 
Proliferation and apoptosis.  Normal colonic epithelium maintains a tightly 
controlled equilibrium of cell growth and cell death (39,40). Typically, colonic cells 
proliferate in the lower part of the crypt and differentiate as they move up the crypt 
(39,40). Finally surface colonocytes undergo apoptosis or are sloughed off into the 
lumen and are lost into the fecal stream (39,40). In the promotion phase of 
carcinogenesis, including colon cancer, alterations of cell dynamics such as proliferation 
and apoptosis occur (35). For example, loss of the highly ordered process of colonic cell 
regeneration may cause the expansion of the proliferative zone towards the lumen or 
beyond the normal proliferative compartment within the crypt (37). In addition, it is 
widely accepted that disruptions of cell proliferation and apoptosis enable mutated cells 
to have a clonal growth advantage over normal cells, which can lead to tumor growth 
(41-43). Thus, measurements of proliferation and apoptosis are valuable biomarkers of 
tumorigenesis (44).  
Certain components in the diet may modulate the promotion phase of 
carcinogenesis by influencing the rate of cell proliferation and apoptosis via various 
mechanisms (45). Some of the components reported in the literature are classic nutrients. 
For example, pectin, a highly fermentable dietary fiber, was shown to increase cell 
proliferation in the distal colon while decreasing apoptosis in the proximal colon (46). 
Another classic nutrient source, dietary corn oil, when provided to azoxymethane-treated 
Sprague-Dawley rats was found to suppress mitochondria-dependent apoptosis via 
inhibiting the tumor suppressor gene p53 (47). More recently, phytochemicals not 
usually considered as classic nutrients, have been the subject of much research. 
Apigenin, a flavonoid commonly found in fruits and vegetables such as oranges and 
onions, was able to inhibit proliferation of human colon carcinoma cell lines (SW480, 
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HT-29, and Caco-2) by inducing cell cycle arrest at G2/M phase (48). Genistein, an 
isoflavonoid found in soybeans, not only induced a G2/M phase cell cycle arrest in HT-
29 cells but also enhanced apotosis of the cells through regulation of p21WAF1 and 
Bax/Bcl-2 expression (49). A compound in green tea, (-)-epigallocatechin-3-gallate 
(EGCG), was found to exert a G1 phase cell cycle arrest in human ovarian cancer cell 
lines (SKOV-3 and OVCAR-3), and induce apoptosis with associated up-regulation in 
p21 and Bax (50). Quercetin, a flavonoid found in apples, onions, and tea, was shown to 
induce G2/M or G0/G1 cell cycle arrest in nasopharyngeal carcinoma cell lines, HK1 
and CNE2, with up-regulation of retinoblastoma gene expression (51). The same study 
also showed that quercetin mediated apoptosis of HK1 and CNE2 by up-regulating pro-
apoptotic protein Bad, and caspases-3 and -7 (51). Therefore, certain nutrients and non-
nutritive bioactive compounds are capable of influencing proliferation and apoptosis by 
changing gene expression and affecting cell cycle checkpoints, as well as inflammation, 
which will be described later. 
 
Aberrant crypt foci as a surrogate biomarker.  In the mid-1980s, preneoplastic 
lesions termed as aberrant crypt foci (ACF) were proposed as distinct histological 
lesions that preceded polyp formation (52) in the polyp-cancer sequence of colon 
carcinogenesis (53). ACF were first detected by Bird (54) in the colons of carcinogen-
injected rodents. Since then, ACF have been hypothesized as the earliest easily 
identifiable precursors to neoplastic lesions in animal models of colon carcinogenesis 
(55,56) and to lead towards colon tumorigenesis in humans (57,58). Under the 
microscope, ACF can be seen as single crypts or clusters of morphologically altered 
colonic crypts in methylene blue-stained colons of chemically treated rodents (55,56) 
and in humans (58,59). Compared to normal colon mucosa, ACF are described to have 
dilated and irregular luminal openings with thickened epithelial linings that appear to 
protrude into the lumen (55,56,58,59). Their occurrence in the colon can range from 
none to hundreds (57). Evidence supports the use of ACF as a surrogate biomarker 
predictive of future colonic tumor development (55-58). Firstly, ACF are present in 
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colons of patients with and before development of colon cancer (58). In addition, ACF 
occur more frequently in the distal part of the human colon, which is in accordance with 
the location of carcinomas observed in colon cancer (58). Genes frequently altered in 
colon cancers, such as APC, K-ras, and p53, had also been shown to be modified in ACF 
(57,58). Furthermore, changes in expression of β-catenin, iNOS, COX-2, and 
microsatelite instability due to defects in the DNA mismatch repair system commonly 
associated with colon cancers had also been demonstrated in ACF (57,58). Finally, the 
clonal and dysplastic nature of certain types of ACF, an important factor in 
tumorigenesis, has been reported (57,58). Cell proliferation was increased and the 
proliferative zone expanded towards the lumen in ACF of chemically treated rodents 
(58). Similarly, ACF with excessive proliferation or severe dysplasia were identified in 
colons of humans with colonic tumors (60). Although less defined in experimentally-
induced ACF, one study reported that apoptisis was lower in ACF than in normal crypts 
of rats (58). Therefore, based on all the evidence discussed above, the ACF stage as an 
end-point is a suitable surrogate biomarker for colon cancer. In addition, the ACF system 
is also generally accepted and widely used to screen for colon chemopreventive agents 
(57,58).   
  
Inflammation.  The inflammatory process had been connected to the 
development of cancer (61,62). In fact, chronic inflammatory conditions such as 
ulcerative colitis have been proposed as a possible pathway to the development of colon 
cancer (5,62). Two pro-inflammatory enzymes, inducible nitric oxide synthase (iNOS) 
and cyclooxygenase-2 (COX-2) have both been implicated in colon carcinogenesis (63-
66). Indeed, enhanced expression of iNOS and COX-2 have been shown in colorectal 
adenomas and adenocarcinomas in humans and chemically induced colonic tumors in 
rats (67-70). 
During chronic inflammation, iNOS activity is greatly induced and excessive 
nitric oxide (NO) production occurs (61). NO has been suggested to modulate cell 
proliferation and apoptosis, induce DNA damage, and act as a reactive nitrogen species 
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(61,71). Using the ACF system, agents that inhibit iNOS also inhibit ACF formation, 
and thus may protect against colon tumorigenesis through this activity (72,73). 
Interestingly, NO is also implicated in the regulation of COX-2 activity (74,75). 
Salvemini et al. (74) demonstrated in both E. coli lipopolysaccaride (LPS)-activated 
macrophages and in LPS-treated male Sprague-Dawley rats that NO inhibition resulted 
in attenuated prostaglandin (PG) synthesis, a major product of the COX enzyme. A later 
study by Landino et al. (75) put forward a possible link between NO and PG synthesis 
by both the COX-1 and -2 enzymes. Peroxynitrite, a coupling product of NO and 
superoxide anion, was found to modify COX activity and suppress PG synthesis (75). 
The authors suggested that peroxynitrite, an inorganic hydroperoxide, may act as a 
substrate for the peroxidase portion of the COX enzyme, thus inducing its activity (75).  
Cyclooxygenases, also known as prostaglandin endoperoxidase (PGH) synthases, 
are key enzymes involved in the production of prostaglandins using arachidonic acid as a 
precursor (76). As alluded to earlier, PGH synthases have both a peroxidase activity and 
a cyclooxygenase activity at two distinct sites (76).  COX-2, the inducible isoform, is not 
usually detectable in normal cells, but its expression and activity are greatly induced in 
inflammation (76). Overexpression of COX-2 has been detected in human colorectal 
tumors (68,69). PGE2, one of the products of COX-2, is implicated in abnormal cell 
proliferation, apoptosis inhibition, induction of angiogenesis, and also has been found at 
increased levels in colon cancer tissue (63,76). Thus, the inhibition of COX-2 levels or 
activity may protect against colon cancer development (76). In rodent models of colon 
carcinogenesis COX-2 inhibitors have been shown to reduce ACF and the incidence, 
multiplicity, and size of tumors (63,76,77).  
There is evidence that both iNOS and COX-2 expression may be modulated by 
certain compounds in the diet (62,78-85). Several flavonoids, including naringenin and 
apigenin, were able to suppress in-vitro expression of iNOS and COX-2 (78,80-82,84). 
In those studies, the flavonoids were found not to inhibit iNOS activity but to attenuate 
its expression at the transcription level (78,81,84). One study by Raso et al. (82), 
however, demonstrated that both expression and activity of iNOS and COX-2 were 
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inhibited by some flavonoids. Although the exact mechanism through which the 
flavonoids were acting has not been elucidated, studies with other phytochemical 
compounds such as curcumin, EGCG, and resveratrol have shed some light on a possible 
mechanism (83). Nuclear factor-kappa B (NF-κB), one the most ubiquitous eukaryotic 
transcription factors, is involved in regulating the transcription of genes promoting 
tumor growth, including the expression of iNOS and COX-2 enzymes (83). NF-κB is 
normally prevented from binding to the nucleus by forming a complex with inhibitory 
protein IκB (83). Curcumin, EGCG, and resveratrol were shown in several in vitro 
studies to possess the ability to inhibit nuclear translocation of NF-κB by blocking the 
breakdown of IκB, thus subsequently suppressing transcription of iNOS and COX-2 
genes (83). 
 
Biological activities of citrus flavonoids and limonoids.  Citrus fruits contain a 
wide variety of phytochemicals, and many such substances are potentially 
anticarcinogenic (19). Flavonoids, a class of polyphenolic compounds, and limonoids, 
classified as triterpenoids, are naturally occurring substances in citrus fruits (86,87). 
Flavonoids are divided into six major classes, depending on variations in their structure, 
into flavones, flavonols, flavanones, catechins, anthocyanidins, and isoflavones (86) 
Flavonoids are observed to possess many biological activities in vitro, including 
antioxidant, antiproliferation, antibiotic, antiallergic, antidiarrheal, antiulcer, anti-
inflammatory, antiestrogenic, and the ability to modify enzyme activity (86,88). The 
amount of data published on limonoids is much less when compared to those on 
flavonoids. Limonoids were discovered initially as bitter agents in citrus juices but 
recent work has demonstrated that limonoids may also contain health promoting 
properties such as being anticarcinogenic and having lipid-lowering effects (87). Indeed, 
certain flavonoids and limonoids present in citrus fruits have shown potential 
chemopreventive properties in both in vitro and in vivo animal models (20-34). In cell 
culture assays, the citrus methoxyflavonoid nobiletin inhibited proliferation of HTB43 
human squamous cell carcinoma cells, A549 human lung carcinoma cells, CCRF-HSB-2 
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human T-cell leukemia, and TGBC11TKB human gastric cancer cells (20,21). 
Naringenin, another citrus flavonoid, inhibited proliferation of HT29 colon cancer cells 
and MDA-MB-435 human breast cancer cells (22,23). A citrus limonoid glucoside 
mixture (69.8% obacunone glucoside, 6.7% limonin glucoside) was shown to inhibit the 
proliferation of MCF-7 human breast cancer cells, with an IC50 of 8.7 µg/ml (24). When 
added to the diets of F344 rats and CF-1 mice, the citrus flavonoids (hesperidin, 
nobiletin, apigenin) and limonoids (limonin, obacunone) lowered the number of 
chemically induced aberrant crypt foci and reduced tumorigenesis of the colon (25-28). 
To our knowledge, there is no study on naringenin and its effects on a rat model of colon 
cancer. However, when provided to Sprague-Dawley rats in an experimental model of 
breast cancer, naringenin reduced the weight of chemically induced mammary tumors by 
52% (23). In addition, hesperidin has been shown to protect against oral tumors in F344 
rats (29) and limonin, limonin glycoside, and obacunone protected against a hamster 
cheek pouch model of oral carcinogenesis (30-32). Limonin has also been shown to be 
protective against chemically induced forestomach, lung, and skin carcinogenesis in 
ICR/Ha and SENCAR mice (33,34).  
Some studies have begun to investigate the mechanisms through which citrus 
flavonoids and limonoids could potentially exert their chemoprotective effects. As 
discussed previously, certain flavonoids were able to inhibit the expression of 
proinflammatory enzymes iNOS and COX-2. Another school of thought focused on the 
free radical scavenging/antioxidant activity of flavonoids as the basis of their 
chemopreventive effects (89,90). Since DNA damage caused by free radicals may be 
one of the pathways linked to carcinogenesis, the anticarcinogenic effects of certain 
flavonoids may be due to their ability to quench free radicals (89,90).  Other possible 
chemoprotective mechanisms suggested are induction of phase II detoxifying enzymes 
and inhibition of protein kinases in signal transduction pathways (91). Certain limonoids 
like nomilin and obacunone were thought to exert their anticarcinogenic effects through 
induction of the phase II detoxifying enzyme, gluththione S-transferase (92).  
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Hypothesis.  Based on evidence from published data discussed above, we 
hypothesized that certain citrus flavonoids and limonoids exert chemopreventive effects 
on the promotion stage of colon carcinogenesis when included in the diet. Specifically, 
our hypothesis was: 
 
Citrus flavonoids (hesperidin, nobiletin, apigenin, naringenin) and limonoids 
(a limonin glucoside/obacunone glucoside mixture) would protect against 
development of aberrant crypt foci (ACF) by an associated decrease in 
colonic cell proliferation and increase in apoptosis via suppression of iNOS 
and COX-2 expression. 
 
Specifically, our objectives were: 
 
1. To determine the effect of dietary hesperidin, nobiletin, apigenin, 
naringenin, and a limonin glucoside/obacunone glucoside mixture on the 
number and multiplicity of aberrant crypt foci in rat colon. 
2. To evaluate if there is a correlation between aberrant crypt foci formation 
and colonic cell proliferation and apoptosis in rats consuming these 
compounds. 
3. To investigate if there is an association between colonic cell proliferation 
and apoptosis and the levels of iNOS and COX-2 expression in colonic 
tissues of rats consuming these compounds. 
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Animals and study design.  The animal use protocol in this study had been 
approved by the University Laboratory Animal Care Committee of Texas A&M 
University and conformed to the National Institute of Health guidelines. Sixty male 
weanling (21-d) Sprague-Dawley rats (Harlan Sprague-Dawley, Houston, TX) were 
individually housed in polycarbonate cages with raised steel grid floors to diminish 
coprophagy and access to bedding. The rats were maintained in a temperature- and 
humidity-controlled animal facility with a 12-h light-dark photoperiod. Food and 
drinking water were freely available. The time line for this study is shown in Figure 1. 
Upon arrival, the rats were acclimated for 5-d and given regular pelleted rat food. On the 
fifth day, the rats were stratified according to their body weights into six groups (10 
rats/group) and started on experimental diets for a total of 10 wk. All rats were injected 
twice with the colon carcinogen azoxymethane (AOM, Midwest Research Institute, 
Kansas City, MO; 15 mg/kg), spaced 1-wk apart. The first injection was given 3-wk 
after starting the experimental diets. Rats were terminated 6-wk after the last AOM 
injection and colon tissues collected. Body weights of the rats and diet intake data were 
recorded for 48-h at 7, 21, 56, and 77-d after starting experimental diets (93). 
 
 
 
 
 
 
 
 
FIGURE 1  Time line of the live animal portion of the experiment. 
Abbreviation: AOM, azoxymethane. 
 
1 wk 3 wk 6 wk 5 d 
Acclimate Experimental diets 
AOM injection 
15 mg/kg body weight 
TerminationStart experimental diets 
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Diets.  There were six experimental diets (basal, 0.1% hesperidin, 0.01% 
nobiletin, 0.02% naringenin, 0.1% apigenin, 0.035% limonin glucoside/obacunone 
glucoside mixture, Figure 2) that contained, with the exception of the basal diet, levels of 
experimental compounds chosen based on concentrations that were shown effective in 
the following studies. Tanaka and his colleagues showed that providing hesperidin at 
0.1% and nobiletin at 0.01% of the diet had significantly suppressed the formation of 
aberrant crypt foci (ACF) in AOM-treated male F344 rats (25,26). In CF-1 mice, feeding 
apigenin at 0.1% of the diet was able to suppress ACF formation (27).  Other studies 
found a significant reduction in DMBA-induced buccal pouch tumors by treating female 
Syrian hamsters with a 3.5% limonin glucoside solution (30-32). In another study done 
by our lab (94), naringin at 0.02% of the diet was fed to Sprague-Dawley rats. To 
compare the effects of naringenin, the aglycone of naringin, with naringin, the same 
concentration was chosen for this study.  
The composition of the experimental diets is shown in Table 1. Except for the 
amount of dextrose and the experimental compounds, all other diet components were 
exactly the same among the six experimental diets. The experimental compounds were 
added at the expense of dextrose. Dextrose, casein, DL-methionine, and AIN-76 mineral 
mix were purchased from Bio-Serv, Frenchtown, NJ; AIN-76 vitamin mix and choline 
bitartrate were purchased from Harlan Teklad, Indianapolis, IN; pectin was purchased 
from Danisco, New Century, KS; corn oil was provided by Traco Labs, Champaign, IL. 
Hesperidin, nobiletin, naringenin, apigenin, and limonin glucoside/obacunone glucoside 
mixture were graciously provided by Texas A&M University-Kingsville Citrus Center. 
Briefly, hesperidin (97% pure), naringenin (96% pure), and apigenin (97% pure) were 
isolated from methanol extracts of powdered dried peel from citrus reticulata, citrus 
junos, and citrus aurantium L., respectively (95). Nobiletin (97% pure) was crystallized 
from hexane extracts of dried citrus peel (96) The limonin glucoside/obacunone 
glucoside mixture (76% pure) was purified from ethanol extracts of citrus seeds and 
molasses (97).  
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Nobiletin: R=R1=OMe 
  R2=H 
 
 
 
FIGURE 2  Structures of the experimental compounds used in this study. 
Adapted from Kawaii et al. (98). 
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TABLE 1 
Composition of experimental diets 
Diet 
components 
Basal 
(Control) 
Hesperidin Nobiletin Naringenin Apigenin LG/OG 
mixture1 
 g/100 g 
Dextrose2 51.06 50.96 51.05 51.04 50.96 51.025 
Casein2 22.35 22.35 22.35 22.35 22.35 22.350 
Pectin3 6.00 6.00 6.00 6.00 6.00 6.000 
Mineral mix2 
(AIN-76) 3.91 3.91 3.91 3.91 3.91 3.910 
Vitamin mix4 
(AIN-76) 1.12 1.12 1.12 1.12 1.12 1.120 
DL-methionine2 0.34 0.34 0.34 0.34 0.34 0.340 
Choline 
bitartrate4 0.22 0.22 0.22 0.22 0.22 0.220 
Corn oil5 15.00 15.00 15.00 15.00 15.00 15.000 
Experimental 
compounds 0.00 0.10 0.01 0.02 0.10 0.035 
1 Limonin glucoside/obacunone glucoside mixture. 
2 Bio-Serv, Frenchtown, NJ. 
3 Danisco, New Century, KS. 
4 Harlan, Indianapolis, IN. 
5 We acknowledge the generous donation of the dietary corn oil by Sid Tracy, Traco Labs, 
Champaign, IL. 
 
 
 
Diets were mixed according to protocol (see Appendix A for diet mixing 
protocol) and stored in a -20°C freezer until use. To determine actual concentration of 
the experimental compounds (hesperidin, nobiletin, naringenin, apigenin, and limonin 
glucoside/obacunone glucoside mixture) in the diets, samples of the diets were analyzed 
by high performance liquid chromatography (HPLC) as  described  previously  (93,99).  
 
Collection of tissue samples.  Six weeks after the second AOM injection, each 
rat was euthanized by CO2 overdose and its entire colon excised. Figure 3 shows a 
schematic diagram of the sectioning of colon tissues. Two, 1-cm sections were cut from 
the distal end of each rat colon. One of the two sections from the distal end was fixed in 
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ethanol (70% EtOH) and the other was fixed in paraformaldehyde (4% PFA). After 
flushing with ice-cold PBS, the remaining colon was split open and cut in half 
longitudinally. One half of the colon was fixed in 70% EtOH for aberrant crypt foci 
assay and the other half was used for collecting protein samples. To collect protein 
samples, colonic mucosal cells were gently scraped off using a glass slide such that only 
the basement membrane was left. The mucosal scrapings were homogenized in a protein 
buffer (10% Tris-HCL, 5% Sucrose, 1% EDTA, 1% EGTA, 0.0125% NaF, 10% Triton 
X-100, 1% Sodium Orthovanadate, 4% Sigma Protease Inhibitor Cocktail, 0.07% Beta-
mercaptoethanol) and the mucosal cells were lysed by passing the mucosal homogenate 
through a 27 gauge fine needle. The mucosal cell lysates were centrifuged at 15,000 g 
for 20 min at 4°C, and the supernatant, containing the released proteins, was aliquoted 
into 13-40 µL samples, and stored immediately in a 80°C freezer (93).  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3  Schematic diagram of rat colon sample collection. Sections were 
used for aberrant crypt foci evaluation, western blot analysis, and immunohistochemistry 
assays. Abbreviation: EtOH, ethanol; PFA, 4% paraformaldehyde. 
Aberrant crypt foci assay 
Protein isolation 
Fixed in 
EtOH 
Fixed in 
PFA 
Distal 
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Evaluation of aberrant crypt foci.  This assay was performed according to the 
procedure of Bird (54), with modifications (93). Each rat colon tissue prepared for this 
assay was aligned in a longitudinally folded piece of Whatman #1 filter paper with 
mucosal side facing up and fixed in 70% EtOH for 24 h. After 24 h of fixation, the colon 
tissue was taken off the filter paper and stained with 0.5% methylene blue. After 
staining, the entire colon was examined under a light microscope using 40X 
magnification for quantification of aberrant crypts. Two or more aberrant crypts 
clustered together were termed an aberrant crypt focus (ACF); a focus with more than 
four aberrant crypts was termed a high-multiplicity ACF. Dysplastic ACF, or ACF with 
a high number of aberrant crypts, are more likely to correlate with subsequent formation 
of adenomas and/or adenocarcinomas, thus more interest is placed on the evaluation of 
high-multiplicity ACF formation (57,58). The following were evaluated in each colon 
sample  high-multiplicity aberrant crypt foci, total aberrant crypts, and aberrant crypts 
per centimeter of colon.  
 
Measurement of cell proliferation.  This assay was performed according to the 
proliferating cell nuclear antigen (PCNA) staining procedure of Zheng et al. (100), with 
modifications (93). Colon tissue from the distal end of each rat colon was fixed in 70% 
EtOH, embedded in paraffin, cut into 4 µm slices, and mounted onto glass slides. The 
deparaffinized and rehydrated tissue sections were incubated with a murine anti-PC-10 
monoclonal antibody (dilution 1:50; Signet Lab, Dedham, MA). Subsequently, tissue 
sections were incubated with biotinylated anti-mouse IgG from the Vectastain ABC Elite 
kit (Vector Lab, Burlingame, CA). Negative control tissues were prepared by incubating 
with PBS instead of anti-PC-10 antibody. Tissue sections were then stained with 
diaminobenzidine tetrahydrochloride (DAB; Sigma Chemical, St Louis, MO) and 
counterstained with hematoxylin (Sigma Chemical, St Louis, MO). PCNA-containing 
nuclei, indicative of proliferating cells, showed up as brown spots within colonic crypt 
columns. Twenty-five crypt columns per rat were selected for analysis. For each crypt 
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column, the proportion of proliferating cells and position of the highest proliferating cell 
were recorded (Figure 4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4  Cartoon illustrating a colonic crypt. A colonic crypt column is one 
side of the colonic crypt (shown above as crypt divided by dashed line). Five surface 
cells immediately after the highest cell of the crypt column were evaluated for incidence 
of apoptosis.  
 
 
 
Measurement of apoptosis.  The incidence of apoptosis in colonic tissues was 
measured by TUNEL assay according to the method of Hong et al. (101). Colon tissue 
(4% PFA-fixed and paraffin embedded) from the distal end of each rat colon was cut 
into 4 µm slices and mounted onto glass slides. The deparaffinized and rehydrated tissue 
sections were pretreated with proteinase K (Ambion, Austin, TX) to remove crosslinking 
caused by PFA. A working solution containing terminal deoxynucleotide transferase 
(TdT)-reaction buffer was incubated with tissue sections in a pre-warmed humidified 
chamber, with the subsequent addition of anti-digoxigenin peroxidase. This step labels 
Surface cells 
Crypt Column 
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the free 3OH termini of DNA fragments (a characteristic of apoptotic cells) with 
digoxigenin via TdT and forms an antibody-antigen complex. Visualization of the 
antibody-antigen complex was accomplished by staining with DAB and counterstaining 
with 1% methyl green. Positive control tissues were prepared by nicking DNA with 
deoxyribonuclease I (Ambion); negative control tissues were prepared by substituting 
PBS for TdT in the working solution. Apoptotic cells, seen as brown spots within 
colonic crypt columns and mucosal surface cells, were quantified for 50 crypt columns 
per rat. For each rat, the proportion of apoptotic cells within each crypt column and 
corresponding mucosal surface cells were recorded (Figure 4). 
 
Western blot analysis of iNOS and COX-2.  Protein concentrations in 
supernatant extracted from the centrifuged colonic mucosal homogenate of each rat were 
determined by a BCA Protein Assay kit according to manufacturers instructions (Pierce, 
Rockford, IL). Thirty micrograms of protein (see Appendix B for western blot protocol) 
were seperated by Novex® 4-12% Tris-Glycine gels for 3 h and 30 min at 15 mA and 
150 v and electrophoretically transferred to Invitrolon PVDF membranes (Invitrogen, 
Carlsbad, CA) for 2 h at 300 mA and 25 v; both processes ran in a 4°C walk-in cooler. A 
color marker, TriChromRanger prestained protein molecular weight marker mix (Pierce, 
Rockford, IL), was loaded into one of the wells of the gel for identification of the 
relative positions of the desired protein bands. After the transfer step, the membranes 
were dipped in methanol and let air-dry. The membranes were then cut horizontally into 
three pieces, using the bands of the color marker as a guide, such that each piece of the 
membrane contained one protein band of interest. The three pieces of membranes were 
individually rehydrated with methanol and processed separately from this step onward. 
After blocking with 2% bovine serum albumin for 1 h at room temperature (Fisher, 
Pittsburg, PA), the membranes were incubated with a goat polyclonal anti-β-actin 
(dilution 1:10,000; Santa Cruz Biotechnology, Santa Cruz, CA), a goat polyclonal anti-
COX-2 (dilution 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA) or a rabbit 
polyclonal anti-iNOS antibody (dilution 1:375; Cayman Chemicals, Ann Arbor, MI) 
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overnight at 4°C. The membranes were subsequently probed with a bovine anti-goat 
(dilution for β-actin 1:300,000; dilution for COX-2 1:60,000; Santa Cruz Biotechnology, 
Santa Cruz, CA) or a goat anti-rabbit IgG-HRP conjugate (dilution 1:60,000; Cayman 
Chemicals, Ann Arbor, MI) for 1 h at room temperature. The antibody-antigen 
complexes on the membranes were developed with a chemiluminescence kit (Pierce, 
Rockford, IL), intensities of bands were captured with a Bio-Rad Fluor-Imager (Bio-Rad 
Lab, Hercules, CA), and quantified using Quantity One software (Bio-Rad Lab, 
Hercules, CA). β-actin was used as a loading control.   
 
Statistical analysis.  Animal weight and diet intake data were analyzed by one-
way ANOVA or a repeated measures model using the Proc GLM or Proc Mixed method 
in SAS (SAS Institute Inc., Cary, NC). Evaluation of ACF, proliferation and apoptotic 
indices, and protein expression levels of iNOS, COX-2, and β-actin were analyzed by 
one-way ANOVA using the Proc Mixed method in SAS (SAS Institute Inc., Cary, NC). 
Pearsons correlation analyses in SAS were used for evaluation between ACF formation 
and proliferation or apoptosis, and between proliferation or apoptosis and iNOS or COX-
2 (SAS Institute Inc., Cary, NC). 
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CHAPTER IV 
 
RESULTS 
 
Diet analysis.  The experimental compounds (hesperidin, nobiletin, naringenin, 
and apigenin) were identified by comparing their retention times with those of known 
standards. After analysis by HPLC, performed in the laboratory at the Fruit and 
Vegetable Improvement Center, Texas A&M University, the concentrations of 
experimental compounds in the diets were determined to be 0.096% for hesperidin, 
0.007% for nobiletin, 0.037% for naringenin, and 0.115% for apigenin. Except for 
naringenin, the concentrations of the compounds in the diets were similar to the intended 
concentrations (0.1% for hesperidin, 0.01% for nobiletin, 0.02% for naringenin, and 
0.1% for apigenin). The discrepency could be due to the human error of measurement 
during the diet mixing step or diet analysis procedure. Since the diet samples that were 
used for HPLC analysis were obtained from the initial mixing of the diets and aliquots of 
samples taken periodically throughout the entire study period, the results of the HPLC 
analysis suggested that the compounds did not degrade extensively during storage at 
−20°C. Due to technical difficulties in analyzing the diet containing limonin 
glucoside/obacunone glucoside mixture and lack of a standard for the limonin 
glucoside/obacunone glucoside mixture, their concentration was not determined.  
 
Food intake and weight gain.  Rats appeared to tolerate the experimental diets 
well as there were no significant differences in food intake (Table 2) among any of the 
diet groups overall and at any of the time points measured. However, the average body 
weight of rats in the apigenin group was less than the body weight of rats from the 
hesperidin, nobiletin, naringenin, and limonin glucoside/obacunone glucoside mixture 
groups measured at day 56, and from all diet groups when measured at day 77 (Table 3). 
When weight gained over the experimental period was considered, there was only a 
difference in weight gained between rats in the apigenin group and the limonin 
glucoside/obacunone glucoside mixture group (Table 3). 
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TABLE 2 
Food intake data for rats in each diet group1 
Amount of food consumed (g/d) 
Diet Group 
Day 7 Day 21 Day 56 Day 77 Overall 
Average 
Basal (Control) 14.9a 17.5a 19.8a 19.6a 17.8a 
Hesperidin 15.3a 18.1a 20.0a 18.9a 17.9a 
Nobiletin 14.9a 18.1a 20.5a 19.4a 18.1a 
Naringenin 14.7a 18.3a 20.8a 19.7a 18.2a 
Apigenin 14.8a 17.6a 18.9a 19.1a 17.5a 
LG/OG mixture2 15.2a 18.2a 20.4a 20.2a 18.4a 
SEM 0.6 0.6 0.8 0.8 0.4 
1 Values given are LSmeans ± SEM, n = 10 rats/group. Means in a column without a 
common letter differ, P < 0.05. 
2 Limonin glucoside/obacunone glucoside mixture. 
 
 
TABLE 3 
Weight data for rats in each diet group1 
Body weight (g) 
Diet Group 
Day 0 Day 7 Day 21 Day 56 Day 77 Weight 
Gain 
Basal (Control) 66.7a 124.6a 194.0a  332.4a,b  381.0a 313.8a,b 
Hesperidin 66.9a 126.5a 199.4a  336.0a  381.3a 313.9a,b 
Nobiletin 67.1a 126.9a 198.3a  336.5a  383.5a 315.8a,b 
Naringenin 67.1a 126.6a 197.5a  338.5a  384.4a 316.8a,b 
Apigenin 66.7a 125.0a 194.5a  320.9b  365.3b 298.0a 
LG/OG mixture2 67.4a 123.8a 196.5a  335.7a  386.5a 318.6b 
SEM 4.3 7.8 7.8       7.8       7.8   9.5 
1 Values given are LSmeans ± SEM, n = 10 rats/group. Means in a column without a 
common letter differ, P < 0.05. 
2 Limonin glucoside/obacunone glucoside mixture. 
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Incidence of aberrant crypt foci.  In rats provided with the experimental 
compounds (hesperidin, nobiletin, naringenin, apigenin, and limonin 
glucoside/obacunone glucoside mixture), the total number of aberrant crypts (AC) per 
colon or the number of aberrant crypts per centimeter of colon were not lower than the 
number in rats provided with the basal diet (control group). These results differ from the 
results reported by Tanaka et al. (25,26) where they saw a significant reduction in total 
AC in F344 rats provided with 0.1% hesperidin or 0.01% nobiletin when compared with 
the control. The reason for the difference may be due to species differences between 
F344 and Sprague-Dawley rats (102,103). There was, however, significantly more total 
aberrant crypts (25%) and number of aberrant crypts per centimeter of colon (28%) in 
rats provided with nobiletin compared to the rats provided with apigenin (P < 0.05, 
Figure 5A and 5B, also see Appendix C). In addition, rats from the nobiletin group also 
had greater numbers of aberrant crypts per centimeter of colon than rats from the basal 
(control) and hesperidin group (21% and 20%, respectively, P < 0.05, Figure 5B, also 
see Appendix C). 
In rats provided with the basal diet, AOM induced an average of 3.94 high 
multiplicity ACF per rat (Figure 6). Dietary naringenin resulted in a 51% lower number 
of high multiplicity ACF (average of 1.94 per rat, P < 0.05). Apigenin lowered the 
number of high multiplicity ACF by 57% to an average of 1.69 per rat (P < 0.05).  The 
number of high multiplicity ACF in rats provided with hesperidin, nobiletin, and limonin 
glucoside/obacunone glucoside mixture were not significantly different from the rats 
provided with the basal diet. 
 
Colonocyte proliferation.  Dietary naringenin lowered both the number of 
proliferating colon cells and the proliferative index by 32% (Table 4, Figure 7, P < 0.05), 
compared to the basal diet. In addition, rats provided with naringenin had a smaller 
proliferative zone (18% lowered, P < 0.05) when compared with rats in the basal group 
(Figure 8). There were no significant differences in the proliferative index or 
proliferative zone in rats provided dietary hesperidin, nobiletin, apigenin, and limonin  
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FIGURE 5  Effects of experimental diets on the total number of aberrant crypts 
per colon (A), and number of aberrant crypts per centimeter of colon (B). Values are 
LSmeans ± SEM, n = 10 rats/group. Bars with different letters are significantly different, 
P < 0.05. 
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FIGURE 6  Effects of experimental diets on incidence of high multiplicity ACF 
per colon. High multiplicity ACF classified as > 4 aberrant crypts/focus. Values are 
LSmeans ± SEM, n = 10 rats/group. Bars with different letters are significantly different, 
P < 0.05. 
 
TABLE 4 
Effect of experimental diets on number of proliferative cells, location of highest 
proliferative cell, and crypt height in colon of Sprague-Dawley rats1 
Diet Group No. of proliferative cells 
Location of highest 
proliferative cell 
No. of cells in crypt 
column (crypt 
height) 
Basal (Control) 6.64a 14.98a 32.05a 
Hesperidin 5.77a,b 13.76a,b 32.16a 
Nobiletin 4.94a,b 12.58a,b 31.21a 
Naringenin 4.47b 12.12b 31.98a 
Apigenin 4.77a,b 12.78a,b 32.11a 
LG/OG mixture2 4.76a,b 12.37b 31.96a 
SEM 0.85 1.10 0.42 
1 Values are LSmeans ± SEM, n = 10 rats/group. Means in a column without a common 
letter differ, P < 0.05. 
2 Limonin glucoside/obacunone glucoside mixture. 
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FIGURE 7  Effects of experimental diets on cell proliferation in rat distal colon, 
measured by proliferative index (number of proliferative cells/number of cells in crypt 
column). Values are LSmeans ± SEM, n = 10 rats/group. Bars with different letters are 
significantly different, P < 0.05.  
 
 
FIGURE 8  Effects of experimental diets on expansion of cell proliferation in rat 
distal colon, measured by proliferative zone (location of highest proliferative 
cell/number of cells in crypt column). Values are LSmeans ± SEM, n = 10 rats/group. 
Bars with different letters are significantly different, P < 0.05.  
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glucoside/obacunone glucoside  mixture  compared  to  rats  provided  the  basal diet. 
However, in addition to rats provided with naringenin, rats provided with the limonin 
glucoside/obacunone glucoside mixture did have a lowered position of the highest 
labeled cell from that of rats provided with the basal diet (Table 4). Colonic crypt 
heights were not found to be different among the diet groups (Table 4). 
 
Apoptosis.  To determine whether apoptosis of colonocytes is enhanced or 
suppressed, quantification of cells undergoing apoptosis is usually measured within 
colonic crypt columns. However, the extent of apoptosis within colonic crypts was 
limited in the present study. Apoptotic cells in the colonic crypts of all rats were not 
significantly different among the six diet groups, except between naringenin and limonin 
glucoside/obacunone glucoside mixture diet groups (Table 5). On the other hand, 
extensive staining of apoptotic cells was observed on the luminal surface. Thus, the 
luminal surface colon cells were evaluated for the extent of apoptosis as well.  There was 
a significantly greater percentage of apoptotic cells on the luminal surface in rats fed 
naringenin and apigenin, when compared to control rats. The luminal surface apoptotic 
index for rats provided with dietary naringenin was 97% and apigenin 78% higher than 
rats provided with the basal diet (P < 0.05, Figure 9). Extent of apoptosis in the luminal 
surface cells in rats given dietary hesperidin, nobiletin, and limonin glucoside/obacunone 
glucoside mixture, however, were not significantly different from control rats (Figure 9).  
 
Expression of iNOS and COX-2.  Prior to performing western blot analysis on 
actual mucosal protein samples, iNOS and COX-2 electrophoresis standards at varying 
concentrations (1000  62.5 pg/µl) were used to confirm the reproducibility and 
consistency of results of the protocol. A representative blot of the linearity test for iNOS 
and COX-2 is shown in Figure 10. The linear regression of the three serial 
concentrations (1000, 500, 250 pg/µl) yielded a slope average of 0.97 for iNOS 
and 0.96 for COX-2. 
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TABLE 5 
Effect of experimental diets on apoptosis within colonic crypt columns in male Sprague-
Dawley rats1 
Diet Group No. of apoptotic cells/crypt column 
Basal (Control) 0.20 ± 0.05a,b 
Hesperidin 0.19 ± 0.05a,b 
Nobiletin 0.22 ± 0.06a,b 
Naringenin 0.32 ± 0.06a 
Apigenin 0.18 ± 0.05a,b 
LG/OG mixture2 0.14 ± 0.04b 
1 Values given are LSmeans ± SEM, n = 10 rats/group. Means in a column without a 
common letter differ, P < 0.05. 
2 Limonin glucoside/obacunone glucoside mixture. 
 
 
 
 
 
  
 
FIGURE 9  Effects of experimental diets on apoptosis in rat distal colon, 
measured by luminal surface apoptotic index (number of surface apoptotic cells/number 
of surface cells). Values are LSmeans ± SEM, n = 10 rats/group. Bars with different 
letters are significantly different, P < 0.05. 
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FIGURE 10  A representative blot of linearity test for iNOS and COX-2. 
Western blot analysis of iNOS and COX-2 electrophoresis standards using 
concentrations of 1000, 500, and 250 pg/µl. 
 
 
 
Trial western blot runs on actual protein samples determined that loading 30 µg 
of protein onto the 1.5 mm thick gels was optimal for band visualization. Since iNOS 
and COX-2 standards were loaded with mucosal protein samples for each gel, 
identification of iNOS and COX-2 protein bands in the mucosal protein samples were 
made by comparing bands that aligned with those from the standards. In addition, a 
protein marker was also loaded in each gel to confirm the identity of the bands according 
to their size (121 kD for iNOS and 72 kD for COX-2, Figure 10). 
There were no differences in the expression of iNOS and COX-2 enzymes in 
colonic mucosa of rats in all the diet groups (Figures 11 and 12, also see Appendix D). 
Interestingly, when the data for rats in all diet groups were combined, there was a 
positive correlation between the levels of iNOS and COX-2 enzyme expression (r = 
0.504, P < 0.05). The levels of β-actin in colonic mucosa of rats in all diet groups were 
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not different, indicating that the amounts of protein loaded were similar for all diet 
groups. 
 
Correlation analysis.  There was no correlation between colonocyte proliferation 
and high multiplicity ACF, or surface cell apoptosis and high multiplicity ACF for any 
of the six diet groups, or when data for all diet groups were combined. However, 
proliferative zone was negatively correlated with surface apoptotic index (r=-0.279, P < 
0.05) when data for all diet groups were combined. In addition, there was a tendency for 
a negative relationship between proliferative index and surface cell apoptosis for the 
pooled data (r=-0.237, P = 0.068). It was also interesting to find that in rats provided 
with naringenin, COX-2 level was positively correlated with proliferative index 
(r=0.896, P < 0.05). 
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FIGURE 11  Effects of experimental diets on the expression levels of iNOS 
enzyme. Values are LSmeans ± SEM, n = 10 rats/group. There were no significant 
treatment differences, P > 0.05. 
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FIGURE 12  Effects of experimental diets on expression levels of COX-2 
enzyme. Values are LSmeans ± SEM, n = 10 rats/group. There were no significant 
treatment differences, P > 0.05. 
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CHAPTER V 
 
DISCUSSION 
 
The aim of this study was to investigate the chemopreventive ability of four 
citrus flavonoids (hesperidin, nobiletin, naringenin, and apigenin) and one citrus 
limonoid mixture (containing limonin glucoside and obacunone glucoside) to protect 
against the promotion stage of AOM-induced colon carcinogenesis in Sprague-Dawley 
rats. Using the formation of precancerous lesions, identified as ACF, as the end-point, it 
was determined that dietary naringenin at 0.037% of the diet and dietary apigenin at 
0.115% of the diet (as determined by HPLC analysis) were able to reduce the incidence 
of dysplastic or high multiplicity ACF (> 4 aberrant crypts per focus) in the rat colon by 
51% and 57%, respectively, from the control diet (P < 0.05, Figure 6). The protection 
was not a result of altered apparent nutrient intake or availability because body weight 
and amount of food consumed by the rats were similar among the diet groups and were 
not adversely affected by including the experimental compounds in their diet (Table 2 
and 3). Although dietary apigenin at 0.1% of the diet has been previously shown to 
inhibit AOM-induced ACF in CF-1 mice (27), to our knowledge, this is the first study 
that showed the ability of naringenin, a major flavonoid found in grapefruit, to reduce 
AOM-induced ACF in Sprague-Dawley rats. Since high multiplicity ACF are more 
likely to correlate with future tumor formation (57,58), these results suggest that dietary 
naringenin and apigenin may protect against AOM-induced colon carcinogenesis. 
Naringenin and apigenin also showed promising chemoprotective effects in other in vivo 
cancer models. So et al. (23) provided naringenin at 0.24% of the diet to female 
Sprague-Dawley rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary 
tumors and observed a reduction in tumor weight from control without adverse effects in 
body weight. Subcutaneous injections of apigenin (0.75 or 1.5 mg/kg body weight) were 
able to significantly inhibit bombesin-enhanced peritoneal metastasis of intestinal 
adenocarcinomas induced by azoxymethane in male Wistar rats (104). 
Hesperidin, nobiletin, and limonin glucoside/obacunone glucoside mixture 
(0.096%, 0.007%, as determined by HPLC analysis, and 0.035% of the diet, 
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respectively), on the other hand, were not observed to suppress ACF formation when 
compared to the control diet in this study. In fact, rats from the nobiletin group had 
higher numbers of aberrant crypts than rats from the apigenin group (25% higher, P < 
0.05, Figure 5), and higher numbers of aberrant crypts per centimeter of colon than rats 
from basal (control), hesperidin, and apigenin groups (21%, 20%, and 28% higher, 
respectively, P < 0.05, Figure 5). Dietary hesperidin at 0.1% and nobiletin at 0.01% of 
the diet, however, was found to inhibit AOM-induced ACF in F344 rats in two studies 
done in Japan (25,26). The differences in the results may be due to strain differences 
between Sprague-Dawley and F344 rats (102,103), the time points at which the animals 
were sacrificed, or insufficient amounts of the flavonoids added to the diets in the 
current study. Taylor et al. (102) showed febrile differences between the two rat strains 
after being immunologically-challenged with intraperitoneal injections of 
lipopolysaccharide. Another research group found that Sprague-Dawley rats were more 
predisposed to certain types of tumors than F344 rats (103). One of the main pioneers 
who developed the ACF model had reported that the numbers of ACF, usually appearing 
within 2 wk after carcinogen injection, may peak at 8 wk and regress, and then reappear 
again at a later time point, usually around wk 20 (56,105). It is worthwhile to point out 
that the two studies in Japan terminated their rats 2 wk after the last carcinogen injection, 
thus there may not be sufficient time for the ACF to reach its peak developmental stage. 
Since our study sacrificed experimental rats 4 wk later than the two studies in Japan, the 
higher numbers of ACF seen in rat colons from the hesperidin and nobiletin diet groups 
may be due to the initial peak stage of aberrant crypt formation. Although hesperidin and 
nobiletin did not appear to be chemoprotective in our study, other studies had shown 
potential health benefits of those compounds in the laboratory setting (20,21,29,98,106). 
One of the most interesting health properties is the potential lipid-lowering effects of 
hesperidin and its aglycone, hesperetin (106,107).  
Several studies reported the chemopreventive properties of citrus limonoids, in 
contrast to the non-chemoprotective results that was observed in our study with the 
limonin glucoside/obacunone glucoside mixture. A group of researchers from Japan fed 
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the aglycone form of limonin or obacunone at 0.02% of the diet and found significant 
inhibition of ACF in AOM-treated F344 rats for both diet groups (28). Thus, it may 
appear that the glycosidic form of limonin and obacunone was not effective in protecting 
against AOM-induced ACF. However, in addition to limonin and to a lesser extent 
obacunone, a 3.5% solution of limonin glycoside was shown to be a potent inhibitor of 
oral tumors in a hamster cheek pouch model for oral carcinogenesis (31,32). Therefore, 
it would be interesting to investigate the antineoplastic effects of a higher concentration 
of the limonin glucoside/obacunone glucoside mixture. 
Loss of control in proliferating cells along with suppression of apoptosis are key 
cytokinetic modifications during tumorigenesis (41-43). In the current study, rats 
provided with naringenin had a reduced proportion of proliferating colon cells and 
smaller expansion of the proliferative zone than the control diet (32% and 38% 
respectively, P < 0.05, Figures 7 and 8). Naringenins ability to suppress cell 
proliferation was observed in parallel with its ability to inhibit high multiplicity ACF, 
which may in part explain the chemoprotective effect. Furthermore, the antiproliferative 
effects of naringenin had been shown with HT29 colon cancer cells (22) and MDA-MB-
435 human breast carcinoma cells (23). Hesperidin, nobiletin, apigenin, and the limonin 
glucoside/obacunone glucoside mixture were not observed to possess antiproliferative 
effects in this study. It is worthwhile to note, however, that several cell culture 
experiments had reported antiproliferative effects for hesperetin, the aglycone form of 
hesperidin, (23), nobiletin (20,21), apigenin (48), and a limonoid glucoside mixture (24).  
In experimental models of colon cancer, apoptosis is traditionally measured 
within colonic crypt columns (see Figure 4). Luminal surface cells between crypts are 
not normally included in the analysis. However, tumors often develop when epithelial 
cells do not undergo apoptosis and instead accumulate on the luminal surface of the 
colon (46), thus it makes sense to measure apoptosis on surface cells. In the current 
study, the extent of apoptosis within the colonic crypt columns was limited, and there 
were no differences in the apoptotic staining index among the diet groups, except 
between diet groups naringenin and limonin glucoside/obacunone glucoside mixture. 
34 
Instead, a higher level of apoptotic staining was observed on surface cells of rat colons. 
When compared to the control diet, surface cell apoptosis was enhanced by 97% and 
78% in rats provided with 0.02% naringenin and 0.1% apigenin, respectively (P < 0.05, 
Figure 9). This effect may further explain naringenins ability to suppress high 
multiplicity ACF observed in this study. In a cell culture experiment, naringenin, applied 
at 40 and 80 µM for a 24-h period, induced caspase-3 mediated apoptosis in HL-60 
leukemia cells (108). Since in colon carcinogenesis, changes in apoptosis may be more 
important in predicting tumorigenesis than cell proliferation alone (44), the up-regulation 
of apoptosis observed with apigenin may provide a possible explanation to apigenins 
ability to inhibit high multiplicity ACF, even though there was no associated decrease in 
cell proliferation. Many natural compounds, including flavonoids, derived from the 
human diet had been shown to modulate the process of apoptosis in cell cultures 
(45,109). The ability of apigenin to induce apoptosis has been reported in a variety of 
cancer cell lines, including human prostate carcinoma DU145 cells (110), human 
cervical carcinoma HeLa cells (111) and in human leukemia HL-60 cells (112). 
Therefore, the results from this study suggest that naturally occurring flavonoids  
naringenin and apigenin, may also modulate apoptosis in animal models. Pro-apoptotic 
effects were not seen in rat colons from hesperidin, nobiletin, and limonin 
glucoside/obacunone glucoside mixture diet groups.  
While there were no statistical correlations between high multiplicity ACF and 
cell proliferation or apoptosis in this study, there was a slight negative correlation 
between proliferative zone within crypt column and surface cell apoptosis when data for 
all six diet groups were pooled (r=-0.279, P < 0.05). There was also a tendency for a 
negative relationship between proliferative index within crypt column and surface cell 
apoptosis for the pooled data (r=-0.237, P = 0.068). These results suggest that cell 
kinetics such as cell proliferation and apoptosis might be modulated in this study but the 
individual effects of each diet were not strong enough to achieve significance. It is 
possible that significance may be achieved if the sample size were larger. In any case, 
the negative relationship between cell proliferation and apoptosis is in agreement with 
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evidence from current literature that increased cell proliferation together with decreased 
apoptosis may serve as a permissive platform for cancer development (41-43). 
Another reason for the development of cancer may be due to inflammatory 
processes (61,62). Increased expression of two pro-inflammatory enzymes, COX-2 and 
iNOS, has been reported in human colorectal adenomas and adenocarcinomas and in 
chemically induced colonic tumors in rats (67-70). In the current study, levels of COX-2 
and iNOS proteins in rat colon mucosa were detected via western blot analysis. 
However, no differences in the levels of COX-2 or iNOS proteins among the six diet 
groups were observed. This may mean that dietary hesperidin, nobiletin, naringenin, 
apigenin, and limonin glucoside/obacunone glucoside mixture do not modulate the 
expression levels of COX-2 or iNOS proteins in this colon cancer model, and that the 
protective effects seen with naringenin and apigenin were not associated with regulation 
of COX-2 or iNOS enzyme expression. However, despite the results of this study, 
several investigations involving cell cultures showed that hesperidin, nobiletin, 
naringenin, and apigenin, with varying potencies, were able to inhibit induction of COX-
2 or iNOS proteins (78,80-82,84).  
One possible explanation for the discrepancy of results between in vitro and in 
vivo studies, may be that most cell culture assays use cancerous cell lines that are 
transformed, so the products of tumor promoting genes, such as iNOS or COX-2 in this 
case, are highly expressed or induced. In addition, the test media usually contain only 
one type of cell line. Consequently, any inhibitory effect by compounds of interest is 
likely to be obvious and significant. On the other hand, animal models present a 
challenge in that there is a diverse mixture of cell types in animal tissues. Also, not all 
cells in a tissue sample are transformed or cancerous, especially at early time points in 
carcinogenesis like the ACF stage. The expression of iNOS and COX-2 may be 
comparatively lower at the precancerous ACF stage than at the tumor or carcinoma 
stage. As a result, any protective effects in such scenarios would more likely be harder to 
detect. Thus, results produced with cell culture assays may not necessarily mean that the 
same results will be observed in higher biological systems such as laboratory rats. Due to 
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the promising in vitro inhibitory effects of hesperidin, nobiletin, naringenin, and 
apigenin on iNOS or COX-2 enzymes, it would be very interesting to find out if the 
inhibitory effects will be observed at the tumor stage as opposed to the ACF stage in an 
animal model. In addition, since the current study only measured the levels but not 
activities of iNOS and COX-2, it would be interesting to determine whether the levels of 
NO and PGE2, the products of iNOS and COX-2 respectively, which are suggested to 
promote tumorigenesis, will be affected by the compounds in the current study.  Raso et 
al. (82) reported that apigenin and, to a lesser extent, naringenin dose-dependently 
suppressed not only iNOS and COX-2 induction but also NO and PGE2 levels in LPS-
stimulated macrophages. 
Interestingly, there was a positive correlation between COX-2 level and 
proliferative zone in rats provided with naringenin (r=0.896, P < 0.05). Evidence in the 
literature suggests that PGE2, one of the products of COX-2 enzyme, promotes cell 
proliferation (76), thus may in part explain the positive correlation observed between 
COX-2 level and cell proliferation in the current study. There was also a positive 
correlation between the enzyme expression levels of iNOS and COX-2 (r = 0.504, P < 
0.05) in the current study, when the data for rats in all diet groups were combined. This 
finding suggests that increased levels of iNOS correlate with increased levels of COX-2. 
Several cell culture studies and animal inflammatory models have shown the co-
induction or co-regulation of iNOS and COX-2 enzymes (83). The positive correlation 
between iNOS and COX-2 may also indicate that these two enzymes work cooperatively 
to create an environment conducive to tumor promotion. In DMBA-induced hamster 
bucal pouch tumors, the levels of iNOS increased concomitantly with COX-2 when 
measured in untreated animals to dysplastic lesions to invasive squamous cell carcinoma 
stages (113).  
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CHAPTER VI 
 
CONCLUSIONS 
 
Dietary naringenin and apigenin showed promise as naturally-occurring 
chemopreventive agents against colon carcinogenesis. It would be interesting to 
investigate other possible mechanisms through which naringenin and apigenin exerted 
their protective effects in vivo. One cell culture study showed the ability of apigenin to 
modulate the mitogen-activated protein kinase signal transduction pathway (114). 
Another study reported on the suppression of protein kinase C in 12-0-tetradecanoyl-
phorbol-13-acetate-(TPA)-mediated tumor promotion of mouse skin by apigenin (115). 
Although hesperidin, nobiletin, and the limonin glucoside/obacunone glucoside mixture 
did not show any protective effects in this model for colon cancer, they should not be 
discounted from future consideration since they have demonstrated effectiveness in other 
disease models. Furthermore, the differences in effect or lack of effect between different 
rat strains provided with the same compounds highlights the fact that higher biological 
systems, especially humans, are heterogeneous and diverse. A compound at a certain 
dosage may be beneficial for a group of people with a certain disease profile but not for 
another. Therefore, more research in the area of bioactive compounds and their 
interaction with disease is needed to determine the optimum nutrition profile for the 
prevention of disease for each individual person. 
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APPENDIX A 
 
DIET MIXING PROTOCOL 
 
 
Prior preparation checklist: 
1. Make sure there are adequate diet components 
2. Test compounds 
3. Adequate clean and labeled tubs and ziplock bags for diet components 
4. Arrange for manpower 
5. Weighing scales (2): 50 g-5 kg and >50 g  
6. Measuring tubs and scoops (& spatulas) 
7. Stirring tool 
8. Adequate labeled diet bags and outer bags 
9. Colored Tapes 
10. Sharpies 
11. Aluminum foil 
12. 5 L jugs for oil (2-3) 
13. Cart, tub for ice and ice 
14. Gloves, bench papers, napkins 
15. Diet specification sheets 
16. Mixing bowl and mixer (2) 
17. Labeled vials and specimen cups for diet samples 
 
Note: Each mixing bowl can only contain up to 20 kg of diet, thus the total weight of 
each diet need to be divided up into 2 to 3 portions 
For each diet group, there will be 2 to 3 portions named Bowl 1, Bowl 2, and 
Bowl 3, if necessary. 
Each Bowl group will consists of 3 tubs plus 1 ziplocked bag of diet components. 
See example below: 
 
Diet Bowl 1 Bowl 2 Bowl 3 
Nobiletin 100 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Tangeretin 200 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Hesperidin 300 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Obacunone 400 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Basal 500 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
LG/OG  600 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Total 18 tubs + 6 ziplocks 18 tubs + 6 ziplocks 18 tubs + 6 ziplocks
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Day 1  Diet components weighing day 
 
GOALS:  1. Measure diets into appropriate tubs and ziplock bags 
   2. Arrange in order 
   3. Seal and store in freezer, if necessary 
   4. Record diet lot numbers 
   5. Document process and take pictures 
 
SUPPLIES:  See checklist 
 
START TIME: 8 AM 
 
LOCATION:  Kleberg basement (diet mixing room) 
 
MANPOWER: At least 2; preferably at least one guy. 
 
PROCEDURE: 1. Transport diet components from storage and/or freezer to   
     mixing room. 
2. Bring supplies to mixing room. 
3. Weigh out diet components (according to specification sheet) in  
     the following order: 
       1st  Dextrose (tub) 
       2nd  Casein (tub) 
       3rd  Pectin (ziplock bag) 
       4th  Salt mix  | 
       5th  Vitamin mix |  all in 
       6th  Methione  |  one tub 
       7th  Choline*  | 
    
4. Arrange tubs that belong to a diet group together; within diet    
    groups, arrange into bowl number. 
5. Store tubs containing salt/vitamin/met/choline mix in freezer. 
6. Record diet lot numbers. 
7. Seal, label and store any excess diet components. 
8. Tidy up. 
 
 
*Note: Choline is kept in a dessicator because it absorbs moisture easily. It will only be 
taken out when it is time to measure choline. Once measured, the choline needs 
to be mixed in with the salt/vitamin mix to ensure dryness. 
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Day 2 and 3  Diet mixing day 
 
GOALS:  1. Measure oil needed for the day 
2. Mix diet components into each diet groups 
   3. Package and double-seal into ziplock bags 
   4. Store diet bags 
   5. Document process and take pictures 
 
SUPPLIES:  See checklist 
 
START TIME: 8 AM 
 
LOCATION:  Kleberg basement (diet mixing room) 
 
MANPOWER: At least 4; preferably at least one guy 
 
PROCEDURE: 1. Get cart, 2-3 5 L jugs, tub big enough to fit jugs and ice,  
     aluminium foil, bench papers, scissors, sharpies, napkins,  
     weigh scale, plastic beaker. 
2. Go to Dr. Chapkins lab to measure out corn oil, where it is also  
     stored. When done, fill remaining barrel of oil with nitrogen  
     gas, seal, date and store back in freezer. Record lot number. 
3. Cover jugs with foil, label, and put on ice. 
4. Bring 2 big stainless steel mixing bowls from lab to basement. 
5. Measure out test compounds, add to salt mix and mix well. 
6. Start with Bowl 1 of a diet group, mix by hand diet components  
    in the following sequence: 
       1. Pectin 
    2. Salt mix 
    3. Casein 
    4. Dextrose 
 7. Fit bowl onto electric mixer, cover, and mix dry components  
     for 5 min at #1 setting. 
8. Still at #1 setting, start mixer for 10 min. During this time, pour  
    oil into mix in 3 separate quantities and times. To get all oil out  
    from jug, use diet to mop it up. 
9. Scrape sides of bowl and blade, mix for 5 min more. 
10. Lower bowl, scrape sides of bowl and blade, put bowl back  
      into position, and mix for 10 min at #2 setting. 
11. Scrape diet off blade, lower and remove bowl. Take a sample  
      of diet mix from 4 locations in the bowl (send for analysis). 
12. Scoop diet into labeled bags and double-bag. Store in labeled  
      plastic tubs in freezer. 
   13. Repeat the above process for all diet groups. Clean up. 
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Notes: Before starting on a new diet group, remember to wash bowls and scoops, and 
change gloves to prevent cross-contamination. 
 
 Equipment like bowls and scoops need to be sprayed with 70% EtOH after 
washing and drying. 
 
The dry diet components are in powder form so dust clouds form when pouring; 
pour slowly to reduce dust. 
 
Salt mix, vitamin mix, and methionine are stored in freezer, so put it back after 
measuring out into tubs. 
 
The salt/vitamin/methione/choline mix might be lumpy so it is best to use gloved 
hands to break up the lumps and mix uniformly. 
 
Diet samples are taken after mixing for analysis of composition. The small vials 
are used to collect samples on mixing day and sent for analysis soon after. The 
big specimen cups are used for collecting diet samples throughout the feeding 
period and analyzed at the end. 
 
54 
APPENDIX B 
 
WESTERN BLOT PROTOCOL 
 
 
For iNOS and COX-2 
Optimized September 2004 
 
Day before: 
1. Prepare Western template (attached). 
2. Identify the samples for WB analysis and organize them in sequence for gel loading 
and for easy retrieval from 800C freezer. 
3. Label 0.6 mL epitubes for number of lanes loaded (1-10). 
4. Make sure that 0.3 g and 0.6 g BSA powder are weighed out and buffers (running 
and transfer buffers; 10X, 2X, and 1X PBS/Tween) are available. 
5. Store in walk-in cooler: deionized distilled water (2 L), running buffer (2 L), and 
transfer buffer.  
6. Transfer buffer to be pre-mixed in bulk (10 L). Add MeOH and 10% SDS to pre-
mixed 2X transfer buffer about 30 min before use. 
7. To be kept cold before use: eppetubes of ddH2O, 2X sample buffer, 1X sample 
buffer (made just before use; 1 part 2X + 1 part ddH2O). 
On the day of Experiment: 
1. Prepare standards first (refer to standard preparation protocol).  
2. Take out and keep markers, standards, samples, 2X and 1X sample buffers, and 
ddH2O on ice. 
NOTE: Switch on the Heating block and set 98°C. 
Make sure protein samples are inverted, flicked, and spun in table-top centrifuge 
prior to pipetting sample from original epi-tube to new epi-tube for reducing protein.  
3. Pipette markers, standards, and samples, Sample Buffer, and ddH2O into 0.6 mL 
eppetubes, mix by flicking and vortexing tubes.  Then quick spin (15 sec) in tabletop 
centrifuge. 
 
Samples: Vol. Protein samples + 2X Sample Buffer + dd H2O 
Standards: iNOS and COX-2 (Cayman); refer to protocol for preparing 
standards 
   10 ABs  iNOS Rabbit polyclonal IgG (Cayman 160862; stored in -20°C) 
COX-2 Goat polyclonal IgG (Santa Cruz 1745; stored in 4°C) 
β-Actin Goat polyclonal IgG (Santa Cruz 1616; stored in 4°C); 
house-keeping protein as loading control 
20 AB:  Bovine anti-goat IgG-HRP conjugate (Santa Cruz 2350) 
Goat anti-rabbit IgG-HRP conjugate (Cayman 10004301) 
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4. Heat samples at 98°C for 10 min (Do Not Heat Marker).   
How to use the heating block: Set the time, temperature, shaking to 300 rpm and 
start. Do steps 1  3 of Gel Preparation.  
5. Remove samples from heating block and keep on ice for 10 sec. Quick spin in the 
tabletop centrifuge; may need a paper towel to wipe the epitubes. Continue step 4 of 
Gel Preparation. 
 
GEL PREPARATION (NOTE: Gels are in walk-in-cooler) 
1. Gel comes in a hard plastic casing enclosed in an outer plastic wrap containing 
buffer. Cut open the outer plastic wrap, drain buffer into the sink, wipe the gels 
inner plastic casing with paper towel, and mark in the center of the wells with 
permanent marker. Gently remove the comb from the gel (Novex® 4-12% Tris-
Glycine Gel 1.5 mm, 10 well, Novex #EC6035), peel off the white tape on the 
casing, and place the gel keeping the notched glass plate face down in the 
electrophoresis unit which is open all the way (unscrew all the way up). Clam gel to 
unit from the sides and leave the bottom at half-open position.  
2. Place the unit in the chamber and pour Tricine SDS Running Buffer (Novex 
#LC1675) until wells are covered. Fill Buffer Chamber with Tricine SDS Running 
Buffer (Novex #LC1675) to the middle of min and max mark (slightly below max. 
line).    
3. Transfer unit into 4°C cold room. Do NOT move unit after loading gels. 
4. Using 10 µl tip and pipette, load the whole amount of markers, standards and 
samples into designated wells (use marks as guides). Change tips every time you 
load the samples. Make sure there is no trapped air in the tip before loading; put the 
tip to the wall where the mark indicating the center of the well is and gently unload 
the tip. 
5. Put lid on electrophoresis unit and connect electrodes to power supply (red to red and 
black to black). 
6. Run at 15 mA and 75 V for about 210-240 min (3.5-4 h), until dye front nears 
bottom of gel (DOUBLE POWER FOR 2 GEL UNITS). Ensure that protein is 
moving to the bottom of the gel after 5 min. Add additional running time if dye front 
is not near bottom of gel. Turn off power supply and unplug unit when finished.  
 
___________Start time             ______beginning V  __   __mA 
___________End time               ______ending V                      ______mA  
 
NOTE: Pour back the running buffer into the running buffer bottle. This could be 
reused until it is cloudy.  
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TRANSFER GEL 
1. Pour some Tris Glycine Transfer Buffer into clean large staining tray. 
2. Soak blotting pads and filter papers in Tris Glycine Transfer Buffer.  
3. Place gel on bench, large side down; crack open gel case with an end of a spatula.  
Cut corner above first lane of gel with a scalpel (right side - top corner).  Using a 
rocking motion with scalpel cut off thickened bottom of gel. Cut off the well 
projections.  
Keep the gel moist with the transfer buffer all the time.  
4. Pick the gel up from the bottom and transfer gel from case to staining tray containing 
transfer buffer - AS IS DO NOT FLIP GEL OVER. Leave for 5 min to equilibrate 
gel with transfer buffer. 
5. Wet membrane (Invitrolon PVDF #LC2005) with methanol to soak ~15 sec (keep 
methanol in a squirt bottle  spray the methanol in the staining tray and then place 
the membrane). Pour out the methanol in the sink and run water for 2-3 min or in the 
waste bottle in the hood. 
6. Grab edge of membrane and place in transfer buffer in the staining tray for 2-5 min, 
swirling to saturate the membrane.   
7. Put transfer cassette into large staining tray (black side down). Open cassette and 
prepare transfer stack by placing one wet sponge on the black cathode side.  
8. Lay one piece of the wet filter paper on the sponge. 
9. Place gel onto filter paper, AS IS, wetting the gel surface with a few drops of 
transfer buffer, to keep moist. 
10. Lay prepared membrane carefully onto gel, avoid trapping any bubbles. 
Do Not Reposisiton The Membrane Once It Contacts The Gel. 
11. Use a glass rod/roller to roll out any bubbles. 
12. Lay other piece of filter paper wetted with transfer buffer on the membrane. Roll out 
any bubbles. 
13. Lay other two packing sponge, wetted with transfer buffer, on the filter paper.  
14. Close cassette, put 300  350 ml transfer buffer, tap the blotting cup to dislodge any 
bubbles, put cassette into the tank, with black side facing labeled black cathode. 
15. Set on the bench on the 4°C cold room. Add cold ddH2O to tank. 
16. Run unit at 300 mA and 25 V for 120 min (2 h) (DOUBLE POWER FOR 2 UNITS).   
Beginning time_________  V_____________ mA___________ 
Ending time____________ V_____________ mA___________ 
To check if everything transferred off the gel onto the membrane, gently place the 
gel into a staining tray with COMASSIE STAIN.  Gently rock for one hour. Destain 
with destainer overnight in cold room. 
17. Prepare 2% BSA/PBS/Tween.  (0.6 g BSA in 30 ml PBS/Tween). 
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18. Put transfer cassette (black side down) into large tray. Open cassette, remove two 
sponges and upper filter paper. Cut the membrane at the first well i.e. right-hand 
side top corner. 
19. Using tweezers, flip membrane over and wash briefly in ddH2O. Transfer to 
staining tray containing MeOH and let saturate for 15 sec Then let dry on filter paper 
for 15 min. 
20. Cut membrane to size according to color marker. Re-wet with MeOH for 15 sec. 
21. Using tweezers, put membrane into 2% BSA/PBS/Tween, shake gently for 3 h in 
4°C cold room or 1 h at RT. 
Ensure the cut corner of the membrane is always on your left side from this step 
onwards.   
NOTE: Discard transfer buffer. 
  
BLOTTING 
1. Prepare 1% BSA/PBS/Tween (0.3 g BSA in 30 ml PBS/Tween). 
2. Pour 1% BSA/PBS/Tween into tray.  Immediately before adding transfer membrane, 
add 1° antibody, and mix gently. 
iNOS 1° AB: 80 µl  COX-2 1° AB: 30 µl  B-actin 1° AB: 3 µl 
3. Put transfer membrane into 1° antibody, shake gently overnight in 4°C cold room. 
Record time and keep time consistent (at least 8 h). 
4. Transfer membrane into tray with 2X PBS/Tween for brief wash. 
5. Pour off PBS/Tween, add new 2X PBS/Tween to tray.  Shake strongly 15 min x 3.  
6. Prepare 1% BSA/PBS/Tween (0.3 g BSA in 30 ml PBS/Tween). 
7. Pour 1% BSA/PBS/Tween into tray. Immediately before adding transfer membrane, 
add 2° Antibody. Shake gently for 1 h at RT.  
   iNOS 2° AB: 0.5 µl  COX-2 2° AB: 0.5 µl  B-actin 2° AB: 0.1 µl 
NOTE: Secondary antibody has cholesterol, so it does not freeze. However, make sure it 
is properly mixed, as it is very dense.    
8. Transfer membrane into tray with 10X PBS/Tween for brief wash. 
9. Pour off PBS/Tween, add new 10X PBS/Tween to tray.  Shake strongly 15 min x 3. 
During this time, gather items for chemiluminescence and imaging. Bio-Rad imager 
is located in room 435.  
10. Just before imaging, mix chemiluminescence substrates gently as below:  
iNOS  Femto Substrate, 0.5 ml each of reagent A and B; incubate 5 min. 
COX-2  Dura Substrate, 0.25 ml each of reagent A and B; incubate 5 min. 
β-Actin  Dura Substrate, 0.5 ml each of reagent A and B; incubate 1.5 min. 
11. Place membrane between acetate sheets. Pipette reagent mixture onto top of 
membrane and gently lower down top acetate sheet such that membrane is 
completely covered with reagent mixture. 
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12. After incubation, place membrane between new acetate sheets (so that reagent mix 
doesnt spill onto Bio Rad reader tray) and image immediately. 
 
In room 435, 
Switch on the phospoimager (Switch is on the left hand side, back; bottom). 
Switch on the computer 
Click on Quantity One program icon 
File --->Flour-S 
    Chemiluminescent 
    Blotting 
     High Resolution 
Open camera door completely and imager door 
Click on Position to check on placement of blot (adjust the blot position and make 
sure the cut end is at the top left hand side)  
Make sure aperture of camera is greater than 1.4 
Place the paper with writing on top of the blot and then focus by rotating the camera 
focus knob.  
After focusing well, enter amount of time for exposure (generally 30-60 sec) 
Then hit ACQUIRE 
If everything is OK (position of the blot and quality), acquire again for 600 sec.  
When done imaging  hold APPLE down and hit B 
           then invert display 
           then autoscale 
adjust the bright and dark as needed 
 
To quantify protein in bands 
>Volume Properties 
 >#5 Volume rectangle 
 > Draw bands around bands of interest 
 >#10 Volume report 
  >click on name, volume and adjusted volume. Print report 
 
Prepare a tub with the following items for Chemiluminasence step: 
1.  Waffle paper liners 
2.  1000P pipette and pipette tips 
3.  Pre-cut acetate sheets or acetate sheets and scissors 
4.  2-mL eppetubes and holder 
5.  Chemiluminacsence substrates  pipette 2 mL of each substrate into separate 
eppetubes 
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6.  Timer 
7.  Blots in PBS/Tween 
8. Waste pipette tips container 
9. Tweezers 
 
Solutions to make/Supplies 
Tricine SDS Running Buffer (1 L) 
100 ml 10X Tricine SDS Running Buffer (Novex#LC1675 from Invitrogen) 
900 ml ddH2O 
Store at 4C 
 
Pre-mixed 2X Tris-Glycine Transfer Buffer (1 L) 
80 ml of 25X TrisGly Transfer Buffer (Novex#LC3675 from Invitrogen) 
780 ml ddH2O 
Add 1 ml of 10% SDS (Sigma L-4522) in 1 L of water 
Store at 4C 
NOTE: Prepare 10 L of the above and store in walk-in cooler. Only add 140 ml MeOH 
to 860 ml of pre-mix ½ h before use. 
 
10 X PBS/ 1% Tween 
1 bottle PBS (Gibco #21600-069) + 1 L ddH2O. Swirl to mix. 
OR use 10X ready prepared PBS 
add 10 g (~10 mL) Tween 20 (Sigma # P-1379). Swirl to mix. 
Store at RT 
 
5X PBS/1% Tween 
Equal parts 10X PBS/Tween and ddH2O 
 
2X PBS/1% Tween (1L) 
200 ml 10X PBS/Tween 
800 ml ddH2O 
 
1X PBS/1% Tween (1L) 
1 packet PBS/Tween powder 
1 L ddH2O 
Coomassie Blue Gel Stain 
0.2 g Coomassie Brilliant Blue R-250 (BioRad #161-0400) 
add 40 mL methanol and add 10 mL acetic acid 
add 50 mL dH2O 
 
Gel Destain for Western 
90 mL methanol 
20 mL acetic acid 
Add 90 mL dH2O 
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SUPPLIES (not specified in protocol) 
Hoefer miniVE Vertical Electrophoresis System #80-6421-05 
Amersham Electrophoresis Power Supply EPS 601 
Bio-Rad PowerPac HC 
Electrophoresis Sample Buffer 2X, Santa Cruz sc-24945 
Acetate sheets, Wiltons office supply, CIL-00010 
Bovine Serum Albumin, Fisher BP 1600-106 
SuperSignal West Dura Extended Duraton Substrate, Pierce #34075 
SuperSignal West Femto Maximum Sensitivity Substrate, Pierce #34095 
TriChromRanger Prestained Protein Molecular Weight Marker Mix, Pierce #26691 
INOS Electrophoresis Standard, Cayman 360862 
COX-2 (Ovine) Electrophoresis Standard, Cayman 360120 
MagicMark XP Western Standard, Invitrogen LC5602 
 
Preparation of COX-2 and iNOS Electrophoresis Standards 
Electrophoresis standards come in 100 ng/µl concentration from supplier. 
Pipette standards into 5 µl aliquots and store in -80°C freezer. 
On day of use, prepare and dilute standards into various concentrations according to 
chart below. 
 
Add 5 µl of 2X sample buffer to 5 µl of standard = 10 µl of 50 ng/µl std. 
Heat at 90°C for 5 min. at 300 rpm on heating block. Cool on ice for 30 sec.  
Spin on bench-top centrifuge for 15 sec. 
Add 40 µl of 1X sample buffer to the 10 µl of 50 ng/µl std. 
You will now have 50 µl of 10 ng/µl std (dilution of 1:5). 
 
For this conc. 
of std 
Add this 
amount 
Of  this To this amount 
Of 1X sample buffer 
You will get 
this final 
amount 
1 ng/µl or 
1000 pg/µl 
5 µl 10 ng/µl std 45 µl 50 µl  
500 pg/µl 5 µl 1000 pg/µl 5 µl 10 µl 
250 pg/µl 5 µl 1000 pg/µl 15 µl 20 µl 
125 pg/µl 5 µl 1000 pg/µl 35 µl 40 µl 
62.5 pg/µl 6 µl 1000 pg/µl 74 µl 80 µl 
 
NOTE: Make sure all eppetubes are finger-flicked and vortexed to properly mix 
the solutions, and spun in bench-top centrifuge before proceeding to the next step. 
 
For loading into gel, you will only need 1 µl of stds at each concentration. 
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WESTERN TEMPLATE 
 
 
Date:      Type of Gel: 
 
Purpose:    
 
 
1° Antibody:     2° Antibody: 
                      
 
 
WELL       SAMPLE      Protein Conc. (ug)       Sample (ul)       Water (ul)         Dye (ul)         
 
1.       
 
2.  
 
3.  
 
4. 
 
5. 
 
6. 
 
7. 
 
8. 
 
9. 
 
10. 
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APPENDIX C 
 
TABLE OF ACF FORMATION 
 
 
Effect of experimental diets on AOM-induced ACF formation in male Sprague-Dawley 
rats1 
Diet Group 
No. of high 
multiplicity 
ACF/colon 
Total no. of 
aberrant 
crypts/colon 
No. of aberrant 
crypts/cm colon 
Basal (Control) 3.94 ± 1.11a 142.80 ± 19.39a,b 13.31 ± 1.73a 
Hesperidin 2.33 ± 0.85a,b 149.50 ± 19.39a,b 13.46 ± 1.73a 
Nobiletin 2.76 ± 0.93a,b 176.10 ± 19.39b 16.92 ± 1.73b 
Naringenin 1.94 ± 0.78b 152.90 ± 19.39a,b 14.16 ± 1.73a,b 
Apigenin 1.69 ± 0.73b 132.00 ± 19.39a 12.24 ± 1.73a 
LG/OG 
mixture2 2.17 ± 0.86
a,b 140.57 ± 20.05a,b 13.74 ± 1.78a,b 
1 Values given are LSmeans ± SEM, n = 10 rats/group. Means in a column without a 
common letter differ, P < 0.05. 
2 Limonin glucoside/obacunone glucoside mixture. 
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APPENDIX D 
 
FIGURE OF WESTERN BLOT 
 
 
 
 
 
Representative blots of western blot analysis on actual mucosal protein samples 
for iNOS and COX-2 enzymes. Abbreviation: Hes, hesperidin, Nob, nobiletin, Nar, 
naringenin, Api, apigenin, LG/OG, limonin glucoside/obacunone glucoside mixture. 
 
Basal 
iNOS 
121 kD 
Hes Nob Nar Api LG/OG
Protein 
Marker 
220 kD
120 kD
100 kD
60 kD 
50 kD 
Basal HesNobNarApi LG/OG 
Protein 
Marker COX-2 
72 kD 
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